Due to the current situation surrounding COVID-19, the Bacteriophage Therapy Summit has been postponed to a later date. Subscribe to receive news and updates on this event.
Bacteriophage Therapy Summit 2020 by Microbiome Movement
The 2nd edition of the Bacteriophage Therapy Summit will be held in Boston, MA from Tuesday 24th March till Thursday 26th March 2020.
What is the Bacteriophage Therapy Summit and Why attend?
The use of bacteriophages in a diversity of fields is a topic that has been raised and looked at by many in the last few years. One of the major factors for this is to find a solution for the rapid increase of antibiotic resistance. In order to develop a concrete solution to the current situation, the regulatory system must be set accordingly and treatments showing efficacy must be produced.
The Bacteriophage Therapy Summit brings together individuals from a diversity of fields, for 3 days in order to explore the current development state and to help identify the possibilities for tomorrow.
Who will be at the Bacteriophage Therapy Summit?
Over 20 speakers and more than 65 companies will be attending.
The summit will bring together individuals in positions and occupations of; Chief/Cxo, President/VP, Directors, Managers, Scientists and Professors. Those who work in a diversity of fields such as; large pharma, biotech, academia and treatment centres.
Agenda for Bacteriophage Therapy Summit 2020
Tuesday 24th March 2020
Workshop A – Steven Theriault CEO & CSO of Cytophage Technologies
Workshop B – Liesl Jeffers-Francis Assistant Professor at the North Carolina A&T State University
Wednesday 25th March 2020
Vincent Fischetti Professor at the Rockefeller University – Phage Lysins As Effective Antibiotic Alternatives
James Cass R&D Manager at Phico Therapeutics – The Implications of Fundamental Phage Biology on the Product Development Pipeline
Jaroslaw Dastych CEO of Proteon Pharmaceuticals – The Role of Bacteriophages as a Microbiome Modulator
Carrie-Lynn Langlais Furr Co-Founder & CEO of Bacteriophage & Drug Development Consultants – Economic Disincentives Are the Greatest Barrier to Phage and Phage-Derived Therapies
Scott Stibitz Chief, Laboratory of Mucosal Pathogens & Cellular Immunology at the FDA – FDA Perspectives on Chemistry, Manufacturing, and Control for Bacteriophage Therapy Products
Rebecca Reindel Medical Officer at the FDA – Early Phase Clinical Development of Bacteriophage
Aleš Štrancar CEO of BIA Separations – Platforms for Fast Purification of Food and Clinical Grade Bacteriophages and Their In-Process Analytics
Duane Morris VP, Operations & CMC at Armata Pharmaceuticals – Armata Pharmaceuticals GMP Manufacturing of Phage Drug Products
Danish Malik Senior Lecturer at the Loughborough University – Scalable Manufacturing, Formulation and Encapsulation of Bacteriophages for Targeted Delivery and Controlled Release
Thursday 26th March 2020
Shawna McCallin Clinical Researcher at the Hopitaux Universitaires de Genève – Moving Clinical Trials for Phage Therapy Forward: Maximizing the Likelihood for Informative and Significant Trials
Sailaja Puttagunta CMO at BiomX – Phage Therapy Treatment of Acne and Other Chronic Diseases
Daniel Sahm VP, Global Microbiology Services & CSO at the International Health Management Associates – Microbiology Support for Phage Therapy Trials: The Devils in the Details
Tuval Ben-Yehezkel CEO of Loop Genomics – Single-Molecule Long-Read Sequencing of Phage Mutational Landscape
Greg Merril Co-Founder & CEO of Adaptive Phage Therapeutics – Ensuring Phage is a Long-Term Viable Treatment Option
Chandrabali Ghose Founder & CEO of Bioharmony Therapeutics – Development of Lysins for the Treatment of Multidrug Resistant Bacterial Infections
Kevin Yehl Postdoctoral Research Associate at Massachusetts Institute of Technology – Engineering Phages to Widen Their Host Range To Overcome Bacterial Resistance Through Tail Fiber Mutagenesis
Xavier Duportet Co-Founder & CEO of Eligo Bioscience – Delivery of Therapeutic DNA Payloads via Phage-Derived Vectors
Conrad Lichtenstein CSO at Nemesis Bioscience – Bacterial Cybergenetics: Resurrecting Sensitivity to Antibiotics in Anti-Microbial Resistant Bacteria
Nancy Tawil VP, Human Health Research at Phagelux – Delivery of Phage-Based Drugs, and Their Incorporation in Medical Devices
Lorenzo Corsini Co-Founder & CEO of PhagoMed – Precision Biofilm Disruption and Vaginome Editing with Phage-Based Drug Candidates
Paul Turner Professor at Yale University – How Can Genome Sequencing Be Used to Identify Functionally Useful Bacteriophage Characteristics to Select Phages for Appropriate Production?
Recap on the Bacteriophage Therapy Summit 2019 – 1st edition
For those who may have missed out on the 1st edition of the Bacteriophage Therapy Summit in 2019, here is a list of speakers at the summit:
Susan Lehman Principal Scientist at AmpliPhi Biosciences
Scott Stibitz Chief, Laboratory of Mucosal Pathogens & Cellular Immunology at the FDA
Rebecca Reindel Medical Officer at the FDA
Carrie-Lynn Langlais Furr VP, Regulatory Affairs & Project Management at AmpliPhi Biosciences
Naomi Zak President & CSO at BiomX
Jeffrey Wager Co-Founder, Chairman & CEO of EnBiotix
Jarosław Dastych CEO of Proteon Pharmaceuticals
Dave Ousterout Co-Founder & CTO of Locus Biosciences
Xavier Duportet Co-Founder & CEO of Eligo Bioscience
Vincent Fischetti Professor at Rockefeller University
Ales Strancar CEO of BIA Separations
Karen Gallant Global Project Director at CARB-X
Yug Varma CEO of Phi Therapeutics
Nancy Tawil Vice President of Human Health Research at Phagelux
Lorenzo Corsini Co-Founder, CEO, R&D of PhagoMed
Heather Fairhead CEO of Phico Therapeutics
Danish Malik Senior Lecturer at University of Loughborough
Clara Leandro Senior Scientist at Technophage
Cara Cassino Executive VP of R&D & CMO at ContraFect
Greg Merril Co-Founder & CEO of Adaptive Phage Therapeutics
Kristin Wannerberger Director R&D Alliance Management at Ferring Pharmaceuticals